CAAS Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

CAAS Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,000	Closed	-$999K	–	1214
2021 Q2	$999K	Hold	100,000	–	–	0.02%	554
2021 Q1	$1.01M	Buy	+100,000	New	+$999K	0.01%	771

Other funds holding EBACU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

CAAS Capital Management's EBACU Position: Q3 2021 in Review

CAAS Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 100,000 shares — an estimated $999K sold.

CAAS Capital Management first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $1.01M in Q1 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

CAAS Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
CAAS Capital Management sold 100,000 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $999K.
CAAS Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
CAAS Capital Management's European Biotech Acquisition Corp. Units position peaked at $1.01M in Q1 2021.
30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.